1. Home
  2. CABR vs PHIO Comparison

CABR vs PHIO Comparison

Compare CABR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CABR

Caring Brands Inc.

N/A

Current Price

$1.16

Market Cap

13.9M

ML Signal

N/A

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.27

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABR
PHIO
Founded
2020
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
14.6M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
CABR
PHIO
Price
$1.16
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.67
AVG Volume (30 Days)
98.7K
235.5K
Earning Date
03-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.81
52 Week High
$1.65
$4.19

Technical Indicators

Market Signals
Indicator
CABR
PHIO
Relative Strength Index (RSI) 57.95 56.15
Support Level $0.78 $1.13
Resistance Level $1.36 $1.43
Average True Range (ATR) 0.15 0.07
MACD 0.00 -0.00
Stochastic Oscillator 67.81 72.22

Price Performance

Historical Comparison
CABR
PHIO

About CABR Caring Brands Inc.

Caring Brands Inc is a consumer wellness company that supports health and wellness through research and development. Its product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. The majority of revenue is generated from the sale of OTC and consumer products, as well as licensing royalties.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: